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Abstract Reliable predictions of immunogenic peptides
are essential in rational vaccine design and can minimize
the experimental effort needed to identify epitopes. In this
work, we describe a pan-specific major histocompatibility
complex (MHC) class I epitope predictor, NetCTLpan. The
method integrates predictions of proteasomal cleavage,
transporter associated with antigen processing (TAP)
transport efficiency, and MHC class I binding affinity into
a MHC class I pathway likelihood score and is an improved
and extended version of NetCTL. The NetCTLpan method
performs predictions for all MHC class I molecules with
known protein sequence and allows predictions for 8-, 9-,
10-, and 11-mer peptides. In order to meet the need for a
low false positive rate, the method is optimized to achieve
high specificity. The method was trained and validated on
large datasets of experimentally identified MHC class I
ligands and cytotoxic T lymphocyte (CTL) epitopes. It has
been reported that MHC molecules are differentially
dependent on TAP transport and proteasomal cleavage.
Here, we did not find any consistent signs of such MHC
dependencies, and the NetCTLpan method is implemented
with fixed weights for proteasomal cleavage and TAP
transport for all MHC molecules. The predictive perfor-
mance of the NetCTLpan method was shown to outperform
other state-of-the-art CTL epitope prediction methods. Our
results further confirm the importance of using full-type
human leukocyte antigen restriction information when
identifying MHC class I epitopes. Using the NetCTLpan
method, the experimental effort to identify 90% of new
epitopes can be reduced by 15% and 40%, respectively,
when compared to the NetMHCpan and NetCTL methods.
The method and benchmark datasets are available at http://
www.cbs.dtu.dk/services/NetCTLpan/.
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Introduction
Cytotoxic T lymphocytes (CTLs) are a subgroup of T
cells able to induce cell death of other cells. CTLs kill
only infected or otherwise damaged cells. In order to
discriminate between infected and healthy cells, all
nucleated cells present host cell peptide fragments on
the cell surface in complex with major histocompatibility
complex class I molecules (MHC class I). Not all
possible peptides originating from cell proteins will be
presented by MHC class I. In fact, it is estimated that
only one out of 2,000 potential peptides will be
immunodominant (Yewdell and Bennink 1999). One of
the first steps involved in MHC class I antigen presenta-
tion is the degradation of intracellular proteins, including
proteins from the cytoplasm and nucleus, by the protea-
some (Larsen et al. 2007; Paz et al. 1999;C r a i ue ta l .
1997; Altuvia and Margalit 2000;M oe ta l .1999;S t o l t z e
et al. 1998; Juncker et al. 2009). These peptides may be
trimmed at the N-terminal end by cytosolic exopeptidases
(Lévy et al. 2002). A subset of the peptides is transported
by transporter associated with antigen processing (TAP)
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class I molecule and the peptide–MHC complex will be
transported to the cell surface, where it subsequently may
be recognized by CTLs. These successive steps from
protein to ligand presented on the cell surface are limiting
the number of possible epitopes. The most restricting step
in antigen presentation is peptide binding to MHC class I
molecule (Yewdell and Bennink 1999).
Reliable predictions of immunogenic peptides can
minimize the experimental effort needed to identify
epitopes. We have previously described a method, NetCTL
(Larsen et al. 2007, 2005), integrating MHC class I binding,
TAP transport efficiency, and proteasomal cleavage pre-
dictions to an overall prediction of CTL epitopes. The
NetCTL method has proven successful in identification of
CTL epitopes from, for instance influenza (Wang et al.
2007), HIV (Pérez et al. 2008), and Orthopoxvirus (Tang et
al. 2008). Several other groups have developed methods for
CTL epitope identification by integrating steps of the MHC
class I pathway (MAPPP, Hakenberg et al. 2003; WAPP,
Dönnes and Kohlbacher 2005); EpiJen, Doytchinova et al.
2006; MHC-pathway, Tenzer et al. 2005). All these
methods are limited by the fact that they only allow for
prediction of peptide binding to a highly limited set of
different MHC molecules. In a large-scale benchmark
evaluation of publicly available server of MHC class I
pathway presentation prediction, Larsen et al. (2007)
showed that the NetCTL method significantly outperformed
all these methods, closely followed by MHC-pathway. The
MHC-pathway method has recently been updated to
include more accurate predictions of MHC binding and a
broader allelic coverage (close to 60 human leukocyte
antigen (HLA)-A and HLA-B alleles are covered by the
default MHC-pathway method in the 2009-09-01 release).
In contrast to this, the NetCTL method has not been updated
since 2007, and the MHC binding prediction remains
limited to the 12 common HLA supertypes (Lund et al.
2004). In the following, we describe an improved and
extended version of NetCTL, called NetCTLpan, which is
able to make predictions for all MHC class I molecules
with known protein sequence. In addition, NetCTLpan can
identify 8-, 9-, 10-, and 11-mer epitopes, as opposed to
NetCTL, which only allowed for prediction of 9-mer
epitopes. The method has been trained on a large data set
of experimentally identified MHC ligands from the SYP-
FEITHI database (Rammensee et al. 1999).
Choosing a performance measure for evaluating a
prediction method is a nontrivial task, and the definition
of performance measure will often influence the benchmark
outcome and subsequent choice of best method. A
commonly used measure for predictive performance is the
area under the receiver operating characteristic (ROC)
curve, the AUC value. This measure integrates the
sensitivity curve as a function of specificity for the range
of sensitivity from one to zero. This measure might not be
optimal if a prediction method is required to have a very
high specificity in order to lower the false positive rate for
subsequent experimental validation. In such situations, it
could be beneficial to use only the high specificity part of
the ROC curve to calculate the predictive performance. To
match such requirements for a low false positive rate, we
have therefore in this work focused on optimizing the
method to achieve high specificity at a potential loss in
sensitivity.
The predictive performance of the NetCTLpan method is
validated on large and MHC diverse data sets derived from
the SYFPEITHI (Rammensee et al. 1999) and Los Alamos
HIV databases (http://www.hiv.lanl.gov/), and its perfor-
mance has been compared to other state-of-the-art CTL
epitope prediction methods.
It has been suggested that supertype-specific differences
exist in how dependent MHC class I presentation of
peptides is on transport via TAP molecules (Brusic et al.
1999; Anderson et al. 1993; Henderson et al. 1992; Smith
and Lutz 1996) and proteasomal cleavage (Wherry et al.
2006). Likewise, it has been suggested that the rescaling
procedure commonly used to correct for possible discrep-
ancies between the allelic predictors (Sturniolo et al. 1999;
Larsen et al. 2005, 2007) could mask genuine biological
difference between MHC molecules and potentially lower
the epitope predictive performance (MacNamara et al.
2009). In the context of the NetCTLpan method, we
investigate to what extend such differences are observed
in large data sets that are diverse with regard to both MHC
restriction and CTL epitopes.
Materials
SYF data set
The SYFPEITHI database (Rammensee et al. 1999) was
used as the source of MHC class I ligands. MHC class I
binding peptides classified as ligands were downloaded in
August 2009. Altogether, the database contained 2,966
HLA class I ligand pairs. Considering only ligands with
length of 8 to 11 amino acids (the lengths for which the
MHC class I binding predictor NetMHCpan can perform
predictions), the data set consists of 2,752 unique HLA
class I ligand pairs. Data used for training the individual
MHC class I pathway predictors—MHC binding (Nielsen
et al. 2007; Hoof et al. 2009), proteasomal cleavage
(Nielsen et al. 2005), and TAP transport efficiency (Peters
358 Immunogenetics (2010) 62:357–368et al. 2003)—was removed from the data set, downsizing it
to 2,309 unique HLA class I ligand pairs.
Peptides in the data set with only serotypic HLA
assignment were assigned to the most common HLA allele
in the European population for this serotype (e.g., the
serotype HLA-A*01 was assigned to the specific allele
HLA-A*0101). The HLA allele frequencies were obtained
from the dbMHC database (http://www.ncbi.nlm.nih.gv/
mhc/). Subsequently, for every peptide, the source protein
was found in the UniProtKB/Swiss-Prot database (Uniprot
Consortium 2009). If more than one matching protein was
a possible source for a peptide, the protein was selected
with preference for human and long protein sequences.
Peptides without corresponding source protein in Uni-
ProtKB/Swiss-Prot were searched against NCBI NR
protein database (http://www.ncbi.nlm.nih.gov). These
steps consequently resulted in the SYF data set consisting
of 2,267 HLA class I ligand pairs with corresponding
source proteins, where 226 ligands are 8-mers, 1,443 are
9-mers, 430 are 10-mers, and 168 ligands belong to the
group of 11-mers. Note, that HLA-C ligands are included
in these numbers. In the evaluation, HLA-C ligands are
merged to a separate test set.
HIV data set
The same HIV data set has been used as for the paper
describing the original NetCTL method (Larsen et al. 2007).
For comparison reasons, the data set has not been updated.
The data set is derived from the Los Alamos HIV database
(http://www.hiv.lanl.gov/). It consists of 216 HLA class I
ligand pairs with corresponding source proteins covering
the 12 supertypes (Lund et al. 2004).
Training and test sets
Each of the HLA alleles in the SYF data set was assigned a
supertype association using the distance measure described
by Nielsen et al. (2007). In short, an HLA allele was
associated to the most similar supertype defined in terms
of the correlation coefficient between NetMHCpan
prediction scores for 1,000,000 random natural 9-mer
peptides for the HLA allele in question and any of the 12
supertype representatives (Larsen et al. 2005). In a few
cases (less than ten), the supertype association was
ambiguous. In these cases, the association was assigned
by applying the classification from the work by Sidney et
al. (2008). The associated supertypes for each HLA class I
allele are shown in Supplementary Table S1.S o m e
supertypes in the 9-mer SYF data set contain more HLA
class I ligand pairs than others. Only four out of the 12
supertypes had more than 100 HLA class I ligand pairs
assigned. In order to minimize bias toward only a few
supertypes, a training data set with maximum 50 randomly
selected ligands per supertype was generated. For seven
supertypes, it was possible to select 50 ligands for the
training set, while the selection for the five remaining
supertypes consisted of between 19 and 47 ligands. This
results in a training set of 504 HLA class I ligand pairs.
Remaining HLA-A and HLA-B ligands not included in
the training data were assigned to a separate set used for
evaluation. This evaluation set covers seven supertypes
and consists of 889 9-mers. All HLA-A and HLA-B
8-, 10-, and 11-mer ligands were merged into another
evaluation set, resulting in a total of 806 ligands. The HIV
data set was used as a third independent evaluation set.
The numbers of ligands per supertypes for the training and
test sets are listed in Table 1.F i n a l l y ,as e to f6 5H L A - C
ligands from the SYFPEITHI database of length 8–11
amino acids was used as a fourth evaluation set.
Methods
MHC class I affinity prediction
The current version of the pan-specific MHC class I
binding prediction method, NetMHCpan-2.2 (Hoof et al.
2009), is an updated version of the original NetMHCpan
method (Nielsen et al. 2007). It has been evaluated as the
best pan-specific method in large benchmark study (Zhang
et al. 2009 and is now including the extension to perform
predictions for 8-, 10-, and 11-mer peptides (Lundegaard et
al. 2008). NetMHCpan-2.2 was trained on a data set of
102,146 quantitative peptide–MHC affinity data points
covering more than 100 distinct MHC molecules. The
prediction server is available at http://www.cbs.dtu.dk/
services/NetMHCpan-2.2/.
Table 1 Numbers of ligands per supertype in the training and test set
Supertype Train Test 9-mer Test 8-/10-/11-mer HIV
A1 36 0 29 5
A2 50 208 94 82
A3 50 49 75 41
A24 19 0 5 9
A26 50 43 74 2
B7 50 8 57 32
B8 28 0 19 5
B62 47 0 27 10
B27 50 224 141 3
B39 50 21 36 1
B44 50 336 227 16
B58 24 0 22 10
Total 504 889 806 216
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The prediction of TAP transport efficiency is based on the
matrix method described in Peters et al. (2003). The
method predicts TAP transport efficiency of peptides by a
scoring method using only the C terminus and the tree
N-terminal residues of a peptide. The contribution to the
prediction score of the N-terminal residues is down-
weighted by a factor of 0.2 in comparison with the score
of the C terminus. In the original publication, the TAP
transport efficiency score was computed as the average of
the values for the 9-mer and its 10-meric precursor. Here,
we extend this approach and predict the TAP transport
efficiency score for peptides of length from 8 to 11 amino
acids, as the average of the values for the original peptide
and its precursor extended by one amino acid N-
terminally. The matrix published in Peters et al. (2003)
was modified as all values in the TAP scoring matrix were
multiplied by a factor of −1, in order to have a high
predicted value corresponding to high transport efficiency.
This way the interpretation is consistent with the predic-
tion of proteasomal cleavage and MHC class I binding
affinity.
Proteasomal cleavage prediction
NetChop C-term 3.0 (Nielsen et al. 2005) was used for
predicting cleavage sites. As in the original NetCTL
publication, only the C-terminal cleavage score of a peptide
was included.
Combined class I pathway presentation
prediction—NetCTLpan
The NetCTLpan prediction value is defined as a weighted
sum of the three individual prediction values for MHC class
I affinity, TAP transport efficiency, and C-terminal protea-
somal cleavage. Optimal relative weights on TAP transport
efficiency and proteasomal cleavage were estimated using
the training data set and based on the average AUC value
per HLA class I ligand pair.
The AUC measure is a commonly used measure for
quantitative tests and model comparison. AUC is the area
under the ROC curve, summarizing the sensitivity as a
function of 1—the specificity. The specificity is given as
1—the false positive ratio defined as the fraction of the
number of correctly predicted nonligands relative to the
total number of nonligands in the dataset (Lund et al.
2005). A specificity of 100% is interpreted as all non-
ligands are actually classified as nonligands. The sensitiv-
ity is the true positive rate (TPR) and is defined as the
number of correctly predicted ligands relative to the total
number of ligands in the dataset. The higher the TPR, the
more actual positives are recognized. The AUC measure
might not be optimal if a prediction method is required to
have very high specificity in order to lower the false
positive rate in subsequent experimental validations. In
such situations, it is beneficial to use only the high
specificity part of the ROC curve to calculate the
predictive performance. Therefore, a search optimizing
the AUC value integrated for specificities from 1 to x
(AUCx), where x [0:1] was performed to optimize the
method to achieve high specificity. High values of x will
focus the method toward high specificity at a potential loss
in sensitivity, whereas low values of x will result in equal
focus on sensitivity and specificity.
When calculating the AUC value, the source protein
was divided into overlapping peptides of the size of the
given ligand. All peptides, except those annotated as
ligands in either the complete SYFPEITHI or Los
Alamos HIV databases, were taken as negative peptides
(nonligands) and the given ligand was taken as positive.
A perfect AUC value of 1.0 corresponds to the ligand
having the highest combined score (NetCTLpan score)
compared to all other possible peptides originating from
the source protein.
Another important issue to resolve is how to calculate
AUC values. Should it have been done per protein, where
an AUC value is calculated for each ligand–HLA–protein
triplet and the performance reported as the average AUC
value over all triplets or should it have been made in a
pooled way, where all peptide data for the different source
proteins and HLA alleles are merged together before
calculating the AUC value? Here, we suggest using the
per-protein measure, since pooling data from different
proteins and HLA alleles will place ligands in a nonbio-
logical competition for presentation. The source proteins in
the SYF ligand data sets have a length distribution varying
from 36 to more than 8,000 amino acids. Applying the
NetCTLpan method to our training set (most homogenous
data set) shows a tendency for shorter proteins having a
lower AUC0.1 than longer proteins. Proteins from our
training set with length of 0–2 0 0h a v eam e a nA U C 0.1 of
0.817, whereas proteins longer than 200 AA have a mean
AUC0.1 of 0.876. The Spearman’s rank correlation
between the protein length and AUC0.1 values for the
training data set is 0.15. This value is significantly
different from random (p<0.001, exact permutation test).
In a pooled evaluation, where source protein data are
merged, the predictive performance would predominantly
reflect the performance for the longer protein. Further, not
all proteins are expressed in equal amounts within the cell
and the presentation of peptides in complex with HLA
molecules happens in competition with the four most
different HLA-A and HLA-B molecules within a given
host and not 46, as it would be the case, when all the HLA
360 Immunogenetics (2010) 62:357–368alleles from the SYF training data set are pooled. Finally,
it is becoming apparent that not all MHC molecules
present peptides at the same binding threshold (Rao et al.
2009). This observation would make an evaluation, where
data for different HLA alleles is pooled, highly problem-
atic, as illustrated in Fig. 1. Here, a ROC curve is shown
for a pooled set of 29 HLA-A*0101, 50 HLA-B*4402,
and 31 HLA-B*5101 ligands using the NetCTLpan
method. In addition, the allele-specific sensitivity (fraction
of ligands identified) for each allele is shown as a function
of the pooled specificity. The figure clearly demonstrates
that different alleles dominate the ROC curve in different
specificity ranges. At a specificity of 0.0025, for instance,
60% (66) of the 110 ligands are identified. Of these are 25
(86% of 29) HLA-A*0101, 32 (62% of 50) are HLA-
B*4401, and only nine (29% of 31) are HLA-B*5101
restricted. At very high specificities, the ROC curve is
thus predominantly shaped by the HLA-A*0101 data, at
intermediate specificities values the curve is shaped by the
HLA-B*4402 data, and finally at low specificity values,
the HLA-B*5101 data defines the curve. This is clearly
not an optimal way of evaluating an overall predictive
performance of a prediction method that is aimed at
achieving uniform prediction accuracy across a broad
range of HLA alleles. To conclude, we find that the
proposed triplet evaluation per ligand–HLA–protein eval-
uation constitutes the least biased approach to evaluate a
prediction method with broad allelic coverage.
Results
The NetCTLpan method
The optimal weights on proteasomal cleavage and TAP
transport efficiency were calculated for AUC fractions
(AUCx) varying x from 0.05 to 1, with a step size of
0.05. With x equal to 1, this corresponds to the conven-
tional AUC value calculation and the way of selecting
optimal weights for the original NetCTL method. The result
of this analysis is shown in Fig. 2. For an AUC fraction of
1, the optimal weights were zero on both proteasomal
cleavage and TAP transport. This implies that NetMHCpan
2.2, the method used for predicting MHC class I binding
affinity, has a very high performance and that adding
predictions for proteasomal cleavage or TAP transport
decreased the overall performance. Figure 2 illustrates that
the more the method is focused on high specificity (low
values of x), the higher the weights and thus importance of
proteasomal cleavage and TAP transport predictions be-
come. This is, however, achieved at a loss in sensitivity at
low specificity values. Based on this observation, the best
performing weights on proteasomal cleavage and TAP
transport were selected using an AUC fraction of 0.1 as
benchmark measure and were found to be 0.225 for
cleavage and 0.025 for TAP. This selection of weights
defines the NetCTLpan method. When interpreting the
weights for cleavage and TAP, keep in mind that the
contribution of the different prediction methods is not
directly reflecting their relative biological contribution in
the pathway.
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Fig. 1 ROC curves for a pooled data set from the HLA-A*0101,
HLA-B*4402, and HLA-B*5101 alleles. The source proteins for all
three alleles were cut into overlapping peptides of the size of the given
ligand, and all peptides except the given ligands were taken as
negative. The data set contained 31 HLA-A*0101, 50 HLA-B*4402,
and 29 HLA-B*5101 ligands, and the predictions were made using the
NetCTLpan method. The black curve shows the ROC curve for the
combined data set. The other three curves show the allele-specific
sensitivity (fraction of ligands identified) as a function of the overall
specificity for each of the three alleles. The insert shows the curves for
the full range of specificities
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Fig. 2 Weights on proteasomal cleavage and TAP transport efficiency
related to AUCx fraction. The smaller the included fraction, the higher
the contribution of proteasomal cleavage and TAP transport efficiency
to a high performance. Optimal weights on proteasomal cleavage and
TAP were found by optimizing the average AUCx value on the SYF
training data set. The dotted line indicates the AUC0.1 fraction
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described method NetCTLpan i ss h o w ni nF i g .3. The overall
AUC value for the NetMHCpan method is 0.980 and the
corresponding AUC0.1 value is 0.852. For the NetCTLpan
method, the overall AUC value is 0.976 and the
corresponding AUC0.1 value is 0.869. These numbers and
the graphs in Fig. 3 illustrate the improved specificity of the
NetCTLpan method compared to NetMHCpan.U pt oa
specificity of 0.85, the ROC curve for NetCTLpan has a higher
sensitivity than NetMHCpan, indicating that this method will
identify more true ligands at a given specificity threshold. On
the other hand, below a specificity of 0.85, the two ROC
curves cross and the NetMHCpan method achieves the highest
sensitivity. This crossover, however, happens at a very low
specificity corresponding to a false positive rate of 0.15 (15%
of the negative peptides are falsely classified as positive) and
is of limited use when doing actual epitope discovery work,
underlining the importance of optimizing the methods on high
specificity.
Table 2 displays the comparison between NetCTLpan
and NetMHCpan for the different data sets using both the
overall AUC and AUC0.1 benchmark measures. Using the
AUC0.1 measure, the NetCTLpan method has a significantly
higher performance compared to NetMHCpan for all data
sets. On the other hand, when comparing the overall AUC
value, the two methods show comparable performance.
Here, for the SYF data set, the NetMHCpan method has
the highest performance, while for the HIV data set and the
HLA-C test set, NetCTLpan performs best. So, if high
sensitivity is essential (even at a cost in specificity), the
NetMHCpan method should be preferred. In more common
situations, where specificity is the more important issue,
NetCTLpan should be the choice.
Results displayed in Table 2 are mean AUC and AUC0.1
values over all ligand–HLA–protein triplets in each data
set. Paired tests were used for comparing performance
between different prediction methods. In Supplementary
Table S2 are given the AUC and AUC0.1 values for each
ligand–HLA–protein triple in the SYFPEITHI data sets.
From this table, it is clear that the predictive performance
does not only vary between supertypes, but also within
supertypes. For the training data set, the difference between
HLA-B*5101 and HLA-B*0702 (both B7 supertype
alleles) for the NetCTLpan method is thus 0.374 in terms
of the AUC0.1 measure. These performance variations
demonstrate the need for large-scale HLA diverse bench-
mark data set to evaluate differences in performance
between prediction methods, as the performance difference
between similar (supertype-wise) alleles often is as high as
the difference for individual alleles between two prediction
methods within a given data set.
Data redundancy
Several ligands appear in the SYFPEITHI ligand data
sets as duplicates restricted to multiple HLA class I
alleles. One might be worried that the potential peptide
Fig. 3 Performance comparison in terms of ROC curves for
NetCTLpan and NetMHCpan. The true positive rate is shown as a
function of the false positive rate. The figure is based on the SYF
training set. The shaded area shows the area under the curve used to
calculate the AUC0.1. The insert shows the complete curves
Table 2 AUC and fractional AUC value comparison between NetCTLpan and NetMHCpan
Data Measure NetCTLpan NetMHCpan p value
Train (9) AUC 0.976 0.980 0.056
AUC0.1 0.869 0.852 0.002
Test (8/9/10/11) AUC 0.977 0.979 0.273
AUC0.1 0.863 0.855 0.002
Test (HIV) AUC 0.933 0.920 0.028
AUC0.1 0.612 0.593 0.106
Test (HLA-C) AUC 0.920 0.866 <0.001
AUC0.1 0.495 0.307 <0.001
The performance values are calculated as average per protein AUC values over the corresponding data sets. p values are calculated by a paired t
test excluding ties. The best performing method is, for each data set and performance measure, highlighted in bold
362 Immunogenetics (2010) 62:357–368similarity/redundancy could influence the performance
estimates of the NetCTLpan method. The training data
set, for instance, consists of 504 HLA ligand pairs, but
only 492 of these are unique peptides. The 9-mer test set
consists of 889 9mer HLA ligand pairs, of which 802 are
unique peptides. The training and 9-mer test sets share 42
identical ligands and three ligands with one mismatch, all
coupled to different alleles. The training set contains four
ligands identical with one mismatch. To investigate the
impact on this data redundancy within the training data set
and between the training and test data sets, we calculated
the performance on redundancy-reduced data sets. The
performance on the training set was calculated by
removing duplicates and ligands with one mismatch and
for the test set by excluding duplicates and ligands with
one mismatch to ligands in the training data. Predictive
performance was shown to be close to identical for both
training and test set, suggesting that peptide redundancy
plays a negligible role in our performance evaluation (see
data in Supplementary Table S3).
MHC affinity rescaling
In contrast to the NetCTL method, the NetCTLpan
method does not use rescaling of predicted MHC class I
affinities. Previously, rescaling has been used to make
prediction values comparable between MHC class I
molecules. It has been suggested that such a rescaling
might remove genuine biological differences between
MHC molecules and potentially lowers the epitopes
predictive performance (MacNamara et al. 2009). To
investigate, if the predictive performance of the NetCTL-
pan method is influenced when including rescaling, we
defined a rescaling factor for each MHC allele and used
that factor to rescale all MHC binding affinity values
before integrating with proteasomal cleavage and TAP
scores. For each allele, the rescaling factor was determined
as the 1 percentile score of the NetMHCpan method for a
set of 1,000,000 random natural 9-mer peptides. An
overall performance gain using rescaling as compared to
not applying rescaling was observed if focusing on the
overall AUC value (no rescaling AUC 0.976 versus
rescaling AUC 0.978, p value 0.006, paired t test). For
high specificity predictions (AUC0.1), however, the meth-
od without rescaling performed similar (AUC0.1 0.869) to
the method using rescaling (AUC0.1 0.868) with a p value
of 0.835. From these results, and to maintain potential
biological differences in specificity between MHC mole-
cules, we chose not to include rescaling in the NetCTLpan
method. One might argue that rescaling versus non-
rescaling cannot influence the performance of the
NetCTLpan method, when the performance is calculated
per ligand–HLA allele, as it is the case in this study. When
focusing on MHC binding predictions alone, this is true
and both methods give identical results. However, when
integrated with proteasomal cleavage and TAP transport
efficiency, this situation changes. Rescaling places all
MHC binding predictions on a similar scale and hence
Table 3 Supertype-specific weights benchmark
Supertype Weights Train Test (8/9/10/11) Test (HIV)
Cleavage TAP Fixed Specific p value Fixed Specific p value Fixed Specific p value
A1 0.050 0.075 0.942 0.950 0.294 0.937 0.936 0.326 0.381 0.455 0.610
A2 0.550 0.000 0.808 0.822 0.133 0.776 0.758 0.008 0.681 0.657 0.104
A3 0.225 0.025 0.890 0.890 0.598 0.872 0.872 (a) 0.648 0.648 (a)
A24 0.000 0.000 0.917 0.942 0.257 0.783 0.895 0.389 0.636 0.636 0.960
A26 0.275 0.025 0.885 0.885 0.476 0.873 0.864 0.006 0.761 0.771 0.500
B7 0.000 0.000 0.710 0.736 0.378 0.765 0.765 0.998 0.493 0.437 0.064
B8 0.725 0.000 0.916 0.920 0.231 0.858 0.870 0.517 0.132 0.144 0.374
B62 0.275 0.200 0.889 0.902 0.014 0.751 0.727 0.345 0.440 0.496 0.303
B27 0.475 0.025 0.911 0.921 0.014 0.921 0.902 0.001 0.370 0.299 0.390
B39 0.175 0.025 0.859 0.860 0.896 0.853 0.849 0.362 0.739 0.711 (b)
B44 0.100 0.025 0.859 0.868 0.127 0.885 0.896 0.001 0.636 0.631 0.845
B58 0.025 0.025 0.959 0.963 0.399 0.820 0.887 0.161 0.774 0.882 0.128
All 0.225 0.025 0.869 0.878 0.016 0.863 0.860 0.143 0.612 0.603 0.300
Optimal weights per supertype are shown. Performance is given as the average AUC0.1 value for each data set. Fixed weights for proteasomal
cleavage and TAP transport efficiency are 0.225 and 0.025, respectively. The higher AUC0.1 value is highlighted in bold for each data set and
supertype
(a) AUC0.1 values are equal for fixed and specific weights, (b) only one sample available for the given supertype
Immunogenetics (2010) 62:357–368 363also places the relative weights on TAP and proteasomal
cleavage on a similar scale across the set of MHC alleles.
This is no longer the case if rescaling is left out. Here,
alleles with low (predicted) binding affinity preference
will have higher relative weights on TAP and proteasomal
cleavage as compared to alleles with high binding affinity
preference.
Supertype-specific weights on proteasomal cleavage
and TAP scores
As mentioned earlier, previous work has suggested that
different MHC molecules have different dependencies
on TAP transport efficiency and proteasomal cleavage.
Based on these observations, it seems natural to find
allele-specific weights for TAP transport and proteaso-
mal cleavage. Due to the small size of the training data
set, we limited ourselves to a search for supertype-
specific weights. For each supertype, we estimated the
weights on proteasomal cleavage and TAP transport that
give optimal average AUC0.1 values. Optimal weights
per supertype and performance values for the different
data sets can be seen in Table 3. It shows that relative
large differences exist between the optimal weights
across the different supertypes. Naturally, the average
AUC0.1 for the training set is higher with supertype-
specific weights as compared to the fixed weights
(estimate for the complete training data set). Applying
these weights resulted in an inconsistent pattern in
performance gain across the different supertypes for the
different test sets when compared to fixed weights. Only
three supertypes (A24, B8, and B58) showed a consistent
performance gain for the SYFPHITHI and HIV test sets
using supertype-specific weights. This result strongly
indicates that optimal weights per supertype are not
reflecting biological differences but occur most likely
due to overfitting. Note that we are not stating that
proteasomal cleavage and TAP transport dependency
could not vary between MHC molecules; we only state
that based on our data, we cannot consistently reproduce
such a differentiated dependency.
Comparison to NetCTL
The comparison of the performance between NetCTLpan
and NetCTL is based on the 9-mer data sets, since NetCTL
is only capable of predicting 9-meric epitopes. Table 4
shows the performance for NetCTLpan and NetCTL on the
different data sets. For both SYF data sets, the NetCTLpan
method significantly outperforms NetCTL. The HIV test set
does not show NetCTLpan being significantly better than
NetCTL. The HIV test set is supertype based, and the HLA
restriction for each HIV epitope is assigned to the
corresponding HLA supertype. This is in contrast to the
SYF ligand data sets, where full typing HLA restriction is
available for most ligands. One hundred nineteen out of
216 HIV peptide supertype pairs are, however, annotated in
the Los Alamos HIV database with full typing for the HLA
restriction. Using this additional information about the
HLA restriction improves the mean AUC0.1 from 0.612 to
0.745 and the overall AUC from 0.933 to 0.959. Both
measurements thus testify NetCTLpan as having a signif-
icantly better performance (both p values <0.001, paired t
test) compared to NetCTL. These results clearly confirm
earlier findings (Pérez et al. 2008; Hoof et al. 2009) of the
importance of going beyond HLA supertypes and the use of
full-type HLA restriction information when identifying
MHC class I epitopes.
To determine the source of the strong gain in predictive
performance between the NetCTL and NetCTLpan methods,
we compared the predictive performance of the NetCTLpan
method to that of NetCTL using the supertype representa-
tive for each HLA allele also for the NetCTLpan method.
This analysis clearly shows (see Table 5) that the shift from
supertype to allele-specific predictions is the main driving
force behind the gain in predictive performance between
NetCTL and NetCTLpan. In all benchmarks has the
NetCTLpan_ST (supertype-specific NetCTLpan method) a
similar predictive performance to that of NetCTL.
Comparison to state-of-the-art MHC class I pathway
prediction methods
Next, we compared the performance of the NetCTLpan
method to the MHC-pathway method (Tenzer et al. 2005).
This method has earlier been shown to be a state-of-the-art
MHC class I pathway predictor (Larsen et al. 2005). Like the
NetCTLpan method, this method integrates predictions of
Table 4 Benchmark comparison of the NetCTLpan and the NetCTL
methods
Data Measure NetCTLpan NetCTL p value
Train (9) AUC 0.976 0.971 0.018
AUC0.1 0.869 0.816 <0.001
Test (9) AUC 0.982 0.975 <0.001
AUC0.1 0.877 0.802 <0.001
Test (HIV) AUC 0.933 0.936 0.366
a
AUC0.1 0.612 0.606 0.600
Average AUC and AUC0.1 values for the NetCTLpan and NetCTL
methods calculated for the SYF train set and the SYF and HIV test sets.
For each data set and performance measure, the best performing method
i ss h o w ni nb o l d .p values are calculated by a paired t test excluding ties
aWhen using full HLA typing information, the NetCTLpan performance
values are 0.959 and 0.745 for AUC and AUC0.1, respectively. Both these
values are significantly higher than the values of NetCTL
364 Immunogenetics (2010) 62:357–368MHC binding, C-terminal proteasomal cleavage, and TAP
transport into a combined pathway presentation score. Here,
we use the method with default parameters via the link http://
tools.immuneepitope.org/analyze/html/mhc_processing.html.
The MHC-pathway method is not pan-specific and hence
does not allow predictions for all HLA class I alleles used in
our benchmark data. Further, it does not allow for predictions
of 8- and 11-mer epitopes and only allows 10-mer epitope
predictions for a subset of the included alleles. To allow for a
fair comparison, we therefore only included ligands from the
SYF data set restricted to HLA alleles covered by the MHC-
pathway method. The results of the benchmark calculation
are shown in Table 6 and clearly show that NetCTLpan
outperforms the MHC-pathway method for all three data sets.
The improved performance is maintained for both the AUC
and AUC0.1 measure. Further, the table shows that the MHC
binding predictors for the two methods have close to
identical performance (NetMHCpan versus MHC). The
cleavage method employed by the NetCTLpan method is
performing consistently better than the immunoproteasome
prediction method used by MHC-pathway (NetChop versus
Immu). The TAP prediction method is identical between the
two methods. These results suggest that the integration
method employed by MHC-pathway is not optimal either
due to the relative low performance of the immunoprotea-
some predictor or as a consequence of how the three
prediction scores have been integrated in the MHC-pathway
method.
Discussion
Earlier work has demonstrated the benefit of integrating
proteasomal cleavage, TAP transport efficiency, and MHC
binding predictions when using reverse immunology to
identify potential CTL epitopes. However, to the best of
our knowledge, none of the publicly available methods
providing this integration are pan-specific and hence do
not allow for prediction of CTL epitopes restricted to any
MHC allele.
Here, we have developed a pan-specific MHC class I
epitope predictor, NetCTLpan. The method integrates
prediction of proteasomal cleavage, TAP transport efficien-
cy, and MHC binding into a MHC class I pathway
presentation likelihood score. In large-scale benchmarks
comprising more than 1,000 MHC class I ligands and CTL
epitopes restricted by close to 60 different HLA alleles, the
method was shown to outperform both the original NetCTL
method, as well as MHC-pathway, another state-of-the-art
class I presentation pathway prediction method.
NetCTLpan was optimized to achieve high specificity in
order to meet the need for a low false positive rate when
Table 6 Benchmark comparison of the NetCTLpan and MHC-pathway methods
Data Measure NetCTLpan MHC-pathway p value NetMHCpan MHC
a TAP NetChop Immu
b N
Train (9) AUC 0.978 0.972 <0.001 0.983 0.981 0.839 0.881 0.803 438
AUC0.1 0.874 0.854 0.01 0.858 0.862 0.278 0.360 0.260 438
Test (9) AUC 0.978 0.974 <0.001 0.978 0.977 0.809 0.870 0.774 615
AUC0.1 0.871 0.847 <0.001 0.864 0.870 0.204 0.362 0.215 615
Test (10) AUC 0.966 0.957 <0.005 0.964 0.966 0.810 0.817 0.734 291
AUC0.1 0.842 0.800 <0.005 0.835 0.824 0.272 0.238 0.180 291
The performance values are calculated as average per protein AUC values for the training and test data sets. The benchmark is made on the subset of the
SYF ligand data sets covered by the MHC-pathway method
aMHC prediction score from MHC-pathway method
bImmunoproteasomal cleavage score from MHC-pathway predictions. The TAP prediction method is identical between the two methods. p value for the
comparison of NetCTLpan to MHC-pathway are calculated by a paired t test excluding ties
Data Measure NetCTL NetCTLpan NetCTLpan_ST
Train (9) AUC 0.971 0.976 0.971
AUC0.1 0.816 0.869 0.830
Test (9) AUC 0.975 0.982 0.971
AUC0.1 0.802 0.877 0.805
Test (8/10/11) AUC NA 0.972 0.961
AUC0.1 NA 0.848 0.770
Table 5 Benchmark comparison
of NetCTL, NetCTLpan,a n d
NetMHCpan_ST (supertype-
specific version of NetCTLpan)
The performance values are
calculated as average per protein
AUC values for the training and
test data sets
Immunogenetics (2010) 62:357–368 365using the method for large-scale epitope discovery. If
focusing on optimal sensitivity, it was shown that the optimal
prediction method should exclude both cleavage and TAP
predictions reducing the method to MHC binding prediction
alone. This is in contrast to earlier work, where proteasomal
cleavage and TAP transport efficiency consistently have been
reported to improve the predictive performance. Whether this
observation reflects true biological aspects of the specificity
overlap between the three pathway players (see for instance
Nielsen et al. 2005) or it simply occurs because the
prediction of MHC class I affinity has gained accuracy
during the recent years, whereas predictors for TAP transport
efficiency and proteasomal cleavage have not changed or
been updated, remains to be seen.
Recent publications have suggested that some MHC
molecules are, compared to others, more or less dependent
on TAP transport and proteasomal cleavage. Using the
NetCTLpan method in large-scale benchmarks, we however
find no consistent signal of such an HLA allele differentiated
dependency of proteasomal cleavage and TAP transport
efficiency. A performance gain using supertype-specific
weights could only be observed for the training set. Applying
these weights to the test sets resulted in an inconsistent
pattern in performance gain for the different supertypes when
compared to fixed weights, indicating that optimal weights
per supertype are not reflecting biological differences but
most likely are a result of overfitting.
NetCTL, the ancestor of NetCTLpan, uses a rescaling of
MHC binding affinity values to make prediction values
comparable between MHC class I molecules. It has been
suggested that such a rescaling might remove genuine
biological differences between MHC molecules and poten-
tially lower the method’s predictive performance. Here, we
show that rescaling has no significant impact on the overall
predictive performance of the NetCTLpan method. Further,
we observed a tendency of different MHC molecules
presenting ligands at different (predicted) binding thresholds.
Based on these observations, the NetCTLpan method is
implemented without use of rescaling, thus maintaining
potential genuine biological differences between MHC
molecules. To allow comparison between presentation
likelihood scores for different MHC molecules, we include
a rank-score for each prediction. The rank-score is calculated
as the percent rank of a given NetCTLpan likelihood score to
a set of 200,000 random natural 9-mer peptides.
Our results on the HIV benchmark data set confirm the
importance of going beyond HLA supertypes and use
full-type HLA restriction information when identifying
MHC class I epitopes. In this benchmark, we found a
significantly improved predictive performance, if full
HLA restriction were used, in comparison to the HLA
supertype information proposed in the original NetCTL
publication.
In contrast to earlier published methods for MHC class I
pathway prediction, NetCTLpan allows for predictions of 8-
to 11-mer CTL epitopes being presented by any MHC class
I molecule of known protein sequence.
NetCTLpan, the method described in this work, has shown
to perform best when focusing on high specificity predictions
for CTL epitope identification. In order to easily grasp the
predictive performance gain, we applied the rank measure as
defined by Larsen et al. (2005). The rank measure reports the
average fraction of epitopes identified as a function of the
percentage rank (percentage of tested peptides) for a set of
proteins. This measure indicates how large a fraction of the
peptides for a given protein needs to be tested in order to
identify the epitope with a given likelihood. To identify new
epitopes with 90% likelihood by use of NetCTLpan, the rank
measure reports that 3.7% of the peptides need to be
experimentally verified. For a hypothetical protein of 300
peptides, this means that on average, 11 peptides need to be
tested in order to identify the epitope. The corresponding
numbers for NetMHCpan and NetCTL are 13 and 17
peptides. Hence, by applying the NetCTLpan method instead
of NetMHCpan, the experimental effort can be reduced by
17%, and compared to NetCTL, approximately 40% fewer
epitopes need to be tested. Based on this, it is clear that
utilizing the NetCTLpan method can minimize experimental
effort needed to identify new CTL epitopes. We believe that
this improved performance, combined with the methods
ability to provide predictions of potential CTL epitopes of
length from 8 to 11 amino acids to any MHC class I
molecules of known sequence, will be useful in both rational
reverse immunogenetic epitope discovery and interpretation
of observed immune responses in HLA diverse patient
cohorts. The NetCTLpan method and benchmark data set
are available at: http://www.cbs.dtu.dk/services/NetCTLpan.
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